Agenus Inc. (NASDAQ:AGEN)’s share price rose 3.3% on Wednesday . The stock traded as high as $4.73 and last traded at $4.68, with a volume of 465,497 shares trading hands. The stock had previously closed at $4.53.

AGEN has been the topic of several research analyst reports. Maxim Group reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Agenus in a research note on Friday, June 10th. Zacks Investment Research raised Agenus from a “sell” rating to a “hold” rating in a research report on Tuesday, July 5th. Finally, HC Wainwright reissued a “buy” rating on shares of Agenus in a research report on Saturday, April 30th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $10.47.

The firm’s market cap is $404.00 million. The stock’s 50-day moving average price is $4.31 and its 200 day moving average price is $3.80.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings results on Thursday, April 28th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.23) by $0.14. On average, equities research analysts anticipate that Agenus Inc. will post ($1.36) earnings per share for the current year.

In other Agenus news, CEO Garo H. Armen purchased 100,000 shares of the company’s stock in a transaction that occurred on Monday, May 9th. The shares were purchased at an average cost of $3.18 per share, with a total value of $318,000.00. Following the completion of the transaction, the chief executive officer now owns 1,346,026 shares of the company’s stock, valued at $4,280,362.68. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Agenus Inc (Agenus) is an immunotherapy company. The Company is engaged in discovering and developing treatments for patients with cancer and other diseases. Its approaches are driven by three platform technologies: Its antibody platform, including Retrocyte Display technology, which is designed to produce human monoclonal antibodies focused on advancing checkpoint modulators (CPMs); its heat shock protein (HSP)-based vaccines, and its saponin-based vaccine adjuvants, QS-21 Stimulon adjuvant (QS-21 Stimulon).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.